Ocular Manifestations of Albinism

Back

Background

Albinism refers to a group of hereditary disorders that involve an abnormality of melanin synthesis or distribution.

The term albinism comes from the Latin word albus, which means white, and, in 1908, Garrod first scientifically described it.[1] Clinically, albinism presents as a pigmentation abnormality of the skin, the hair, and/or the eyes. Albinism can be divided into 2 broad categories, as follows: oculocutaneous albinism and ocular albinism. Oculocutaneous albinism involves both the skin and the eyes, whereas ocular albinism mainly affects the eyes with minimal to no skin involvement.

The primary morbidity of both oculocutaneous albinism and ocular albinism is eye related. Signs and symptoms include photophobia, refractive errors, monocular vision, strabismus, pendular nystagmus, iris transillumination defects, foveal hypoplasia, and abnormal decussation of the optic nerve fibers. These ocular manifestations are almost always present in both forms of albinism; however, the degree of their presentation can vary depending on the type of albinism and the racial background of the patient.

The inheritance pattern of albinism is also quite variable. Oculocutaneous albinism is mostly an autosomal recessive disorder, whereas ocular albinism is transmitted as a sex-linked or autosomal recessive disease.

Oculocutaneous albinism is divided into approximately 10 different types. Two of the more common forms are type I (tyrosinase negative)[2] and type II (tyrosinase positive) oculocutaneous albinism. Patients with type I disease have no skin or ocular pigmentation, whereas those with type II disease can develop some pigmentation as they grow older.

Another important form of oculocutaneous albinism is type IB, which was previously called yellow mutant oculocutaneous albinism. Patients with type IB are similar to those with type I but can exhibit some pigmentation of their skin, hair, and ocular structures.

Two additional rare types of oculocutaneous albinism with important systemic findings and an increased risk of mortality are Hermansky-Pudlak syndrome and Chediak-Higashi syndrome.

Ocular albinism type I is an X-linked disorder associated with the OA1 gene. Type I is the most common form of ocular albinism. Female carriers can show minor signs, whereas males with ocular albinism can show a constellation of any of the above-mentioned findings.[3]

The visual acuity in patients with albinism is variable and ranges from 20/40 to 20/400.[4, 5]

Pathophysiology

Melanin is the pigment responsible for skin, hair, and eye coloration. Albinism is caused by a disorder of melanin metabolism, and the defect can lie with either melanin synthesis or distribution. Melanin is synthesized in melanocytes from the amino acid tyrosine. This process takes place in special organelles called melanosomes. The pathophysiology of oculocutaneous albinism involves a reduction in the amount of melanin present in each of the melanosomes. The pathophysiology of ocular albinism is a reduction in the number of melanosomes, although each melanosome may be fully pigmented.

The most important enzyme in the synthesis of melanin is tyrosinase, which converts tyrosine to dopa. The gene for the enzyme tyrosinase has been localized to chromosome 11. A number of mutations have been found at this locus, which can result in an absent or defective tyrosinase enzyme. This results in type I oculocutaneous albinism, which is characterized by complete absence of skin and eye pigmentation, despite a normal number of melanosomes.

In contrast, the type II (tyrosine positive) oculocutaneous albinism defect is within the P polypeptide, which is a melanosomal tyrosine transporter. The P gene has been mapped to chromosome 15 and is more commonly linked with albinism in patients of African descent. These patients do have some pigment, but they have lighter pigmentation than expected due to their relatives and ethnicity.

Ocular albinism type I is an X-linked disorder related to defects in the OA1 gene. This gene produces pigment cell-specific, intracellular G-protein coupled receptor 143 (GPR143),[6] which appears to result in faulty transport of melanosomes and lysosomes as well as macromelanosomes. Patients with this disorder are found to have giant melanosomes in their skin melanocytes and retinal pigment epithelium.

The exact mechanism by which the absence of pigmentation leads to foveal hypoplasia and abnormal decussation of optic nerve fibers is not completely understood. It has been postulated that retinal pigment epithelial pigmentation around the macula is necessary for the normal development of the fovea. It also has been suggested that the absence of dopa, which is an antimitotic agent, can influence normal retinal development. This foveal hypoplasia is responsible for some degree of decreased visual acuity in almost all types of albinism. The abnormal decussation of optic nerve fibers is responsible for strabismus and monocular vision. Photophobia results from iris transillumination defects.

Epidemiology

Frequency

United States

The frequency of type I (tyrosinase negative) oculocutaneous albinism is approximately 1 in 17,000 to 1 in 20,000.

The frequency of type IB albinism appears to be higher among Amish people.

The frequency of type II (tyrosinase positive) oculocutaneous albinism is higher in the African American population, where it can be 1 in 10,000, as compared to 1 in 36,000 in Caucasian Americans.

The prevalence of X-linked ocular albinism is estimated to be 1 in 50,000.

International

The frequency of type I oculocutaneous albinism worldwide is about the same as in the United States.

The frequency of type II oculocutaneous albinism is higher in African countries, where it can range from 1 in 2000 to 1 in 5000.

Similarly, the frequency of Hermansky-Pudlak syndrome is much higher in Puerto Rico, where it is approximately 1 in 2700.

Mortality/Morbidity

The main cause for morbidity in patients with albinism is decreased visual acuity.

In tropical regions, there can be higher mortality among these patients secondary to an increased incidence of skin cancer due to sun exposure.

Mortality also is increased in patients with Hermansky-Pudlak syndrome and Chediak-Higashi syndrome. Patients with Hermansky-Pudlak syndrome have a bleeding diathesis secondary to platelet dysfunction and also experience restrictive lung disease, inflammatory bowel disease, cardiomyopathy, and renal disease. Patients with Chediak-Higashi syndrome are susceptible to infection and also can develop lymphofollicular malignancy.

Race

Albinism affects all racial groups. However, type II oculocutaneous albinism occurs more frequently in African American and African populations. Similarly, there is a much higher incidence of Hermansky-Pudlak syndrome among people of Puerto Rican origin.

Sex

Oculocutaneous albinism affects both sexes equally. Ocular albinism is a disease primarily of males because of its sex-linked transmission.

Age

Most people with albinism are diagnosed during infancy or early childhood.

Prognosis

Visual prognosis in patients with albinism is quite variable. Usually, no improvement in visual acuity occurs in patients with type I oculocutaneous albinism. Visual acuity may improve with increased pigmentation in other forms of albinism as the patient grows older.

History

Patients with albinism usually present in early infancy and generally will have any of the following symptoms:

Physical

All children with nystagmus should be evaluated for foveal hypoplasia and transillumination defects. Patients with subtle external pigment changes may be misdiagnosed with congenital motor nystagmus if these signs are missed.

Most patients with albinism generally have a combination of the physical findings discussed below.

Most patients with oculocutaneous albinism have obvious hair and skin discoloration. The range of skin and hair colors can vary depending on the type of albinism. Patients with ocular albinism usually have almost normal skin and hair color, but they tend to have lighter skin and hair color than their siblings, especially in darker skin populations.

The color of the iris usually is blue but can vary from blue to brown. Almost all patients have iris transillumination defects, which can be seen with direct or retroillumination at the slit lamp.

Visual acuity usually is decreased and can range from 20/40 to 20/400. Refractive errors are common and can be either myopic or hyperopic.

Patients usually have monocular vision and poor stereopsis secondary to abnormalities of the optic pathways. Patients have an increased amount of crossed nerve fibers in the optic chiasm. Patients have abnormal retinogeniculostriate projection; many of the temporal hemiretinal nerve fibers decussate rather than project to the ipsilateral geniculate body. Strabismus generally is seen and is mostly esotropic in nature. A pendular type of nystagmus is present.

Foveal hypoplasia with an absent foveal reflex is almost universal,[7] and the ophthalmoscopic signs of macular and foveal hypoplasia include the following:

The fundus, in general, is hypopigmented. Female carriers of X-linked albinism can have macular pigmentary mottling as well as abnormal pigmentation of the peripheral fundus.

McCafferty et al noted that, while foveal hypoplasia is the hallmark of albinism, its morphology and development can be quite variable.[8]

Causes

Albinism is a hereditary condition. No apparent conditions seem to predispose a person to develop albinism.

Laboratory Studies

Oculocutaneous albinism and ocular albinism are primarily clinical diagnoses.

The tyrosinase hair bulb incubation test is a simple test that can differentiate between tyrosinase-negative and tyrosinase-positive forms of albinism. Hair bulbs from a patient with albinism are incubated with tyrosine in a test tube. Hair bulbs from tyrosinase-positive patients demonstrate some degree of pigment production, while those from tyrosinase-negative patients have no pigment production. Since most of the albino phenotypes are tyrosinase positive, this test provides limited information in determining the exact type of albinism.

Simple blood clotting tests can be performed if Hermansky-Pudlak syndrome is suspected. The clotting parameters are reduced in patients with this disease because of defective platelets.

Imaging Studies

The visual-evoked potential (VEP) may be used to help confirm the diagnosis of albinism. Patients with albinism show an asymmetry of VEP between the 2 eyes secondary to misrouting of the optic pathways. This makes VEP a very accurate diagnostic test for albinism.

In a study of 13 patients, Seo and colleagues used optical coherence tomography (OCT) to develop a grading system based on foveal hyporeflectivity, the degree of choroidal transillumination, the presence of a tram-tract sign, and foveal depression.[10] They found that these measurements correlated with the visual prognosis.[10]

Macular OCT can be helpful in making a diagnosis of atypical cases of oculocutaneous albinism as reported by Rossi et al.[11] According to authors, OCT showed high reflectivity across the fovea without foveal depression in an atypical case of oculocutaneous albinism and helped in making the correct diagnosis. These OCT findings are a typical pattern for oculocutaneous albinism.[12]

In a study by Sepúlveda-Vázquez et al, spectral-domain optical coherence tomography (SD-OCT) showed development of inner retinal layers in the fovea, abnormality of the Henle layer, and lack of thickening in the perifoveal area.[13]

Anterior segment OCT can also be used to detect iris abnormalities associated with albinism and can help in making the diagnosis and evaluating the intensity of albinism, as reported by Sheth et al.[14]

A concentric macular ring sign can be seen via infrared reflectance, as reported by Cornish et al.[15]

Prins et al noted that MRI can help in determining the structural changes in brain and visual pathways and can also help as a diagnostic tool and in development of future treatment modalities.[16]

Mohammad et al reported on the morphologic abnormalities of the optic nerve head in patients with albinism using scleral domain OCT. They found that patients with albinism have significantly smaller cup-to-disc ratios and that their peripapillary retinal nerve fiber layer was significantly thinner than that in the control group.[17]

Other Tests

Light microscopy of the blood smear can be performed in patients suspected of having Chediak-Higashi syndrome. The blood smear from these patients shows neutrophils with large inclusions.

Even though not routinely performed, electron microscopic study of the skin or the hair bulbs is probably the best diagnostic method for albinism.

Even though still not widely available, gene sequence analysis can be performed to differentiate between various forms of albinism.

Procedures

A skin biopsy can be performed to make the diagnosis of albinism in cases that are not clinically obvious. Skin biopsy also is helpful to determine the female carrier state in cases of X-linked ocular albinism.

Histologic Findings

Histologic evaluation of the skin, hair, and eyes from patients with oculocutaneous albinism reveals a generalized absence of melanin pigment. There is also an absence of foveal differentiation and generalized deficiency of retinal pigment. Lipidlike deposits can be present in ciliary and iris epithelia. In addition, abnormal melanin macroglobules are present in melanocytes. These macroglobules are present not only in the iris, ciliary epithelium, and retinal pigment epithelium but also in dermal melanocytes. These macroglobules are also present in the skin biopsy of carrier females of X-linked ocular albinism. (It should be emphasized here that, even though the subdivision of albinism into oculocutaneous and ocular forms is helpful to the clinician, it is not entirely accurate histopathologically. All forms of ocular albinism involve, to a small degree, cutaneous pigment abnormalities.) Patients with Hermansky-Pudlak syndrome have a ceroidlike material present in their tissues.

Medical Care

No specific medical treatment is available. Refractive errors should be corrected, and some patients benefit from bifocal lenses. If visual acuity is severely impaired, these patients can be helped with telescopic and other low-vision devices.

Schulze Schwering et al reported improvement of visual acuity with proper refraction in patients with oculocutaneous albinism in Malawi. They found the most improvement in patients with mild to moderate myopia, while the patients with greater than +1.5 D hyperopia did not improve much.[18]

Surgical Care

Surgical management in patients with ocular involvement is limited to ocular muscle surgery.

Strabismus surgery for esotropia or exotropia can be considered for better ocular alignment.

Large 4 muscle horizontal rectus recessions have been reported to improve visual acuity in some patients with nystagmus.

If coexistent retinal disease is present and laser photocoagulation is required (eg, for patients with diabetic retinopathy or retinal tears), laser treatment may be ineffective. Laser photocoagulation requires pigment in the retinal pigment epithelial cells for adequate absorption of laser energy.[19] If the pigment is insufficient for adequate absorption of energy, cryopexy may be used as an alternative to treat peripheral retinal lesions. For posterior retinal pathology, the cryopexy probe is not accessible and no alternative treatment is available.

Sinha et al reported on the surgical challenges and outcomes of retinal detachment repair in 10 patients with albinism. Four of their patients underwent scleral buckling procedure, and six underwent pars plana vitrectomy with silicone oil. They found that patients in both groups did well, and only two patients in the vitrectomy group developed recurrent retinal detachment after three months. They also noted that identifying the retinal breaks, creating a posterior vitreous detachment, and applying endolaser were challenging in these patients.[20]

Farahi et al reported good outcomes of cataract surgery combined with aniridia ring in patients with oculocutaneous albinism. They found that these patients had not only improved visual acuity but also significant reduction in glare and photophobia after surgery.[21]

Consultations

Depending on patient presentation and historical or physical findings, appropriate consultations from various subspecialties should be obtained, as follows:

Prevention

Since there is an increased risk of skin cancer in these patients, they should be advised to use skin tanning lotion and proper clothing for protection against exposure to sunlight.

Long-Term Monitoring

Examine patients with oculocutaneous albinism and ocular albinism periodically to monitor their visual development and to assess the status of their refractive error and/or strabismus.

What is albinism?What is the pathophysiology of albinism?How does the US frequency of albinism differ among subtypes?How does the global frequency of albinism differ among subtypes?What is the morbidity associated with albinism?Which factors increase the mortality risk of albinism?Which types of albinism have racial predilections?What are the sexual predilections of ocular albinism?When is ocular albinism typically diagnosed?What is the visual prognosis of albinism?What are the signs and symptoms of albinism?Which physical findings are characteristic of albinism?What causes albinism?Which disorders are included in the differential diagnoses of albinism?What are the differential diagnoses for Ocular Manifestations of Albinism?What is the role of lab testing in the workup of albinism?What is the role of imaging in the workup of albinism?What is the role of microscopy in the workup of albinism?What is the role of skin biopsy in the workup of albinism?Which histologic findings are characteristic of albinism?How are the ocular manifestations of albinism treated?What is the role of ocular surgery in the treatment of albinism?Which specialist consultations are beneficial to patients with albinism?How is skin cancer prevented in patients with albinism?What is included in the long-term monitoring of albinism?

Author

Mohammed O Peracha, MD, Associate Physician, Midwest Eye Center

Disclosure: Nothing to disclose.

Coauthor(s)

Dean Eliott, MD, Associate Director, Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School

Disclosure: Nothing to disclose.

Enrique Garcia-Valenzuela, MD, PhD, Clinical Assistant Professor, Department of Ophthalmology, University of Illinois Eye and Ear Infirmary; Consulting Staff, Vitreo-Retinal Surgery, Midwest Retina Consultants, SC, Parkside Center

Disclosure: Nothing to disclose.

Frances M Cosgrove, MD, Resident Physician, Department of Ophthalmology, Indiana University School of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

J James Rowsey, MD, Former Director of Corneal Services, St Luke's Cataract and Laser Institute

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy, Sr, MD, † Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Disclosure: Nothing to disclose.

Additional Contributors

Kilbourn Gordon, III, MD, FACEP, Urgent Care Physician

Disclosure: Nothing to disclose.

References

  1. Garrod AE. Inborn errors of metabolism. Lecture II. Lancet. 1908. 2:73-79.
  2. Giordano F, Simoes S, Raposo G. The ocular albinism type 1 (OA1) GPCR is ubiquitinated and its traffic requires endosomal sorting complex responsible for transport (ESCRT) function. Proc Natl Acad Sci U S A. 2011 Jul 19. 108(29):11906-11. [View Abstract]
  3. Tsang SH, Sharma T. X-linked Ocular Albinism. Adv Exp Med Biol. 2018. 1085:49-52. [View Abstract]
  4. Dijkstal JM, Cooley SS, Holleschau AM, King RA, Summers CG. Change in Visual Acuity in Albinism in the Early School Years. J Pediatr Ophthalmol Strabismus. 2011 Jul 6. 1-6. [View Abstract]
  5. Merrill K, Hogue K, Downes S, Holleschau AM, Kutzbach BR, MacDonald JT, et al. Reading acuity in albinism: evaluation with MNREAD charts. J AAPOS. 2011 Feb. 15(1):29-32. [View Abstract]
  6. De Filippo E, Schiedel AC, Manga P. Interaction between G Protein-Coupled Receptor 143 and Tyrosinase: Implications for Understanding Ocular Albinism Type 1. J Invest Dermatol. 2017 Feb. 137 (2):457-465. [View Abstract]
  7. Brücher VC, Heiduschka P, Grenzebach U, Eter N, Biermann J. Distribution of macular ganglion cell layer thickness in foveal hypoplasia: A new diagnostic criterion for ocular albinism. PLoS One. 2019. 14 (11):e0224410. [View Abstract]
  8. McCafferty BK, Wilk MA, McAllister JT, Stepien KE, Dubis AM, Brilliant MH, et al. Clinical Insights Into Foveal Morphology in Albinism. J Pediatr Ophthalmol Strabismus. 2015 May-Jun. 52 (3):167-72. [View Abstract]
  9. Filloux FM, Hoffman RO, Viskochil DH, Jungbluth H, Creel DJ. Ophthalmologic features of Vici syndrome. J Pediatr Ophthalmol Strabismus. 2014 Jul 1. 51 (4):214-20. [View Abstract]
  10. Seo JH, Yu YS, Kim JH, et al. Correlation of visual acuity with foveal hypoplasia grading by optical coherence tomography in albinism. Ophthalmology. 2007 Aug. 114(8):1547-51. [View Abstract]
  11. Rossi S, Testa F, Gargiulo A, Di Iorio V, Pierri RB, D'Alterio FM, et al. The role of optical coherence tomography in an atypical case of oculocutaneous albinism: a case report. Case Rep Ophthalmol. 2012 Jan. 3(1):113-7. [View Abstract]
  12. Meyer CH, Lapolice DJ, Freedman SF. Foveal hypoplasia in oculocutaneous albinism demonstrated by optical coherence tomography. Am J Ophthalmol. 2002 Mar. 133(3):409-10. [View Abstract]
  13. Sepúlveda-Vázquez HE, Villanueva-Mendoza C, Zenteno JC, Villegas-Ruiz V, Pelcastre-Luna E, García-Aguirre G. Macular optical coherence tomography findings and GPR143 mutations in patients with ocular albinism. Int Ophthalmol. 2014 Oct. 34 (5):1075-81. [View Abstract]
  14. Sheth V, Gottlob I, Mohammad S, McLean RJ, Maconachie GD, Kumar A, et al. Diagnostic Potential of Iris Cross-sectional Imaging in Albinism Using Optical Coherence Tomography. Ophthalmology. 2013 May 29. [View Abstract]
  15. Cornish KS, Reddy AR, McBain VA. Concentric macular rings sign in patients with foveal hypoplasia. JAMA Ophthalmol. 2014 Sep. 132 (9):1084-8. [View Abstract]
  16. Prins D, Hanekamp S, Cornelissen FW. Structural brain MRI studies in eye diseases: are they clinically relevant? A review of current findings. Acta Ophthalmol. 2015 Sep 11. [View Abstract]
  17. Mohammad S, Gottlob I, Sheth V, Pilat A, Lee H, Pollheimer E, et al. Characterization of Abnormal Optic Nerve Head Morphology in Albinism Using Optical Coherence Tomography. Invest Ophthalmol Vis Sci. 2015 Jul. 56 (8):4611-8. [View Abstract]
  18. Schulze Schwering M, Kumar N, Bohrmann D, Msukwa G, Kalua K, Kayange P, et al. Refractive errors, visual impairment, and the use of low-vision devices in albinism in Malawi. Graefes Arch Clin Exp Ophthalmol. 2015 Apr. 253 (4):655-61. [View Abstract]
  19. Gangwe AB, Parchand SM, Azad RV, Agrawal D, Bhatia P. Successful treatment of aggressive posterior retinopathy of prematurity with diode laser in ocular albinism: A case report. Indian J Ophthalmol. 2019 Jun. 67 (6):962-964. [View Abstract]
  20. Sinha MK, Chhablani J, Shah BS, Narayanan R, Jalali S. Surgical challenges and outcomes of rhegmatogenous retinal detachment in albinism. Eye (Lond). 2016 Mar. 30 (3):422-5. [View Abstract]
  21. Farahi A, Hashemi H, Mehravaran S. Combined cataract surgery and aniridia ring implantation in oculocutaneous albinism. J Cataract Refract Surg. 2015 Nov. 41 (11):2438-43. [View Abstract]
  22. Abadi R, Pascal E. The recognition and management of albinism. Ophthalmic Physiol Opt. 1989 Jan. 9(1):3-15. [View Abstract]
  23. Carden SM, Boissy RE, Schoettker PJ, et al. Albinism: modern molecular diagnosis. Br J Ophthalmol. 1998 Feb. 82(2):189-95. [View Abstract]
  24. Creel D. Problems of ocular miswiring in albinism, Duane's syndrome, and Marcus Gunn phenomenon. Int Ophthalmol Clin. 1984 Spring. 24(1):165-76. [View Abstract]
  25. Creel D, Witkop CJ Jr, King RA. Asymmetric visually evoked potentials in human albinos: evidence for visual system anomalies. Invest Ophthalmol. 1974 Jun. 13(6):430-40. [View Abstract]
  26. Creel DJ, Summers CG, King RA. Visual anomalies associated with albinism. Ophthalmic Paediatr Genet. 1990 Sep. 11(3):193-200. [View Abstract]
  27. Davis PL, Baker RS, Piccione RJ. Large recession nystagmus surgery in albinos: effect on acuity. J Pediatr Ophthalmol Strabismus. 1997 Sep-Oct. 34(5):279-83; discussion 283-5. [View Abstract]
  28. François J. Albinism. Ophthalmologica. 1979. 178(1-2):19-31. [View Abstract]
  29. Garner A, Jay BS. Macromelanosomes in X-linked ocular albinism. Histopathology. 1980 May. 4(3):243-54. [View Abstract]
  30. Hermansky F, Pudlak P. Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies. Blood. 1959 Feb. 14(2):162-9. [View Abstract]
  31. Ilia M, Jeffery G. Retinal mitosis is regulated by dopa, a melanin precursor that may influence the time at which cells exit the cell cycle: analysis of patterns of cell production in pigmented and albino retinae. J Comp Neurol. 1999 Mar 15. 405(3):394-405. [View Abstract]
  32. Jeffery G. The retinal pigment epithelium as a developmental regulator of the neural retina. Eye. 1998. 12 (Pt 3b):499-503. [View Abstract]
  33. Jeffery G, Schutz G, Montoliu L. Correction of abnormal retinal pathways found with albinism by introduction of a functional tyrosinase gene in transgenic mice. Dev Biol. 1994 Dec. 166(2):460-4. [View Abstract]
  34. Kerr R, Stevens G, Manga P, et al. Identification of P gene mutations in individuals with oculocutaneous albinism in sub-Saharan Africa. Hum Mutat. 2000. 15(2):166-72. [View Abstract]
  35. King RA, Hearing VJ, Creel DJ. Albinism. Scriver CR, Beauder AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York: McGraw Hill; 1995. 4353-92.
  36. Kinnear PE, Jay B, Witkop CJ Jr. Albinism. Surv Ophthalmol. 1985 Sep-Oct. 30(2):75-101. [View Abstract]
  37. Kriss A, Russell-Eggitt I, Harris CM, et al. Aspects of albinism. Ophthalmic Paediatr Genet. 1992 Jun. 13(2):89-100. [View Abstract]
  38. Lyle WM, Sangster JO, Williams TD. Albinism: an update and review of the literature. J Am Optom Assoc. 1997 Oct. 68(10):623-45. [View Abstract]
  39. O'Donnell FE Jr, Green WR, Fleischman JA, et al. X-linked ocular albinism in Blacks. Ocular albinism cum pigmento. Arch Ophthalmol. 1978 Jul. 96(7):1189-92. [View Abstract]
  40. Oetting WS. Albinism. Curr Opin Pediatr. 1999 Dec. 11(6):565-71. [View Abstract]
  41. Oetting WS, Brilliant MH, King RA. The clinical spectrum of albinism in humans. Mol Med Today. 1996 Aug. 2(8):330-5. [View Abstract]
  42. Oetting WS, King RA. Molecular basis of albinism: mutations and polymorphisms of pigmentation genes associated with albinism. Hum Mutat. 1999. 13(2):99-115. [View Abstract]
  43. Oetting WS, Summers CG, King RA. Albinism and the associated ocular defects. Metab Pediatr Syst Ophthalmol. 1994. 17(1-4):5-9. [View Abstract]
  44. Palmisano I, Bagnato P, Palmigiano A, Innamorati G, Rotondo G, Altimare D, et al. The ocular albinism type 1 (OA1) protein, an intracellular G protein-coupled receptor, regulates melanosome transport in pigment cells. Hum Mol Genet. 2008 Aug 18. [View Abstract]
  45. Schiaffino MV, Tacchetti C. The ocular albinism type 1 (OA1) protein and the evidence for an intracellular signal transduction system involved in melanosome biogenesis. Pigment Cell Res. 2005 Aug. 18(4):227-33. [View Abstract]
  46. Smith SA, Wong PK, Jan JE. Unilateral alpha reactivity: an electroencephalographic finding in albinism. J Clin Neurophysiol. 1998 Mar. 15(2):146-9. [View Abstract]
  47. Spritz RA. Molecular genetics of oculocutaneous albinism. Hum Mol Genet. 1994. 3 Spec No:1469-75. [View Abstract]
  48. Summers CG, Knobloch WH, Witkop CJ Jr, et al. Hermansky-Pudlak syndrome. Ophthalmic findings. Ophthalmology. 1988 Apr. 95(4):545-54. [View Abstract]
  49. Weleber RG, Pillers DA, Powell BR, et al. Aland Island eye disease (Forsius-Eriksson syndrome) associated with contiguous deletion syndrome at Xp21. Similarity to incomplete congenital stationary night blindness. Arch Ophthalmol. 1989 Aug. 107(8):1170-9. [View Abstract]
  50. Witkop CJ Jr, White JG, Nance WE, et al. Classification of albinism in man. Birth Defects Orig Artic Ser. 1971 Jun. 7(8):13-25. [View Abstract]